SAB Biotherapeutics (NASDAQ: SABS), gained 28% today as the clinical-stage biopharmaceutical company pioneering a novel immunotherapy platform received approval from the Australian Human Research Ethics Committee (HREC) to initiate the first-in-human Phase 1 clinical trial of SAB-142. Type 1 Diabetes Asset: SAB-142 is a fully-human anti-thymocyte immunoglobulin designed to modify the progression of type 1